Clean energy investments declined 12.1% last year to $254 billion due to the reduced cost of photovoltaic systems and changes in investor confidence as a result of US and European policy changes. In fact, European investments fell 40.9% to $57.8 billion. China, the largest investor, reduced its investments for the first time in more than […]
Based on preliminary figures, US federal budget authority for R&D fell 7.1% in fiscal year 2013 (FY13) to $133.5 billion due to the sequestration. In FY12, it declined 0.4%. Nondefense R&D budget authority fell 3.6% to $61.5 billion, compared to a 4.4% increase in FY12. By budget function, nondefense budget R&D authority for health, natural […]
CROs are projected to be the leading growth market for the instrument industry in 2014. Pharmaceutical and biotechnology firms are increasingly outsourcing analytical research activities and clinical trials, especially those located in China. The CRO market is followed closely by biotech, agriculture/food, hospital/clinical and pharmaceutical labs, all with similar analysis requirements, especially utilizing mass spectrometry […]
Thermo and Life The pending merger (see IBO 4/15/13) will create an industry behemoth and creates new challenges for competitors, such as those in the lab distribution market. It also will provide Thermo with a commanding position as a supplier to pharmaceutical and biotechnology companies for both instruments and consumables. The integration process will be […]
Another Rough Year Last year was a challenging year for analytical instrument makers in many respects. Slower industrial markets and the US government sequestration, which curtailed demand from government and academic markets, resulted in modest sales growth for many companies. Chinese sales growth slowed overall and, although Europe stabilized, sales growth was uneven. Some companies […]
The instrument industry’s performance in 2013 was even more disappointing than in 2012, as a modest rebound was anticipated. Widespread economic malaise and disruptive budgeting decisions, especially in the US, generated considerable uncertainty about future business prospects. Such uncertainty negatively impacted lab capital expenditures. The very real economic effects of budget sequestration in the US […]
As part of the US Centers for Medicare & Medicaid Services’ (CMS) final 2014 Medicare physician fee schedule (PFS) released in November, the CMS has announced a new process for reviewing payment amounts for tests that are part of the Clinical Laboratory Fee Schedule (CLFS). The CLFS sets the price paid by Medicare for clinical […]
The FDA has announced that it plans to revise the language of two draft food safety rules, which were announced in January as part of the Food Safety Modernization Act’s Produce Safety Rule and Preventive Controls for Human Food (see IBO 1/31/13). The rules proposed standards for the produce industry and safety requirements for food […]
According to a report by EuroStemCell, the Kyoto University Institute for Integrated Cell-Material Sciences and Elsevier based on an analysis of publications in the Scopus database, stem cell research is growing rapidly. Stem cell research publications totaled 21,193 in 2012 to make up 1% of global scientific publications. Between 2008 and 2012, the number of […]
The US government has announced a budget agreement that eliminates sequestration for fiscal 2014. As a result, non-defense discretionary spending is estimated to increase 4.7% to $491 billion. However, final appropriations for individual agencies have yet to be determined. Optimism is high regarding budgets for research agencies because the standard budget process, in which Congressional […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
